Drug intelligence / Profile preview

JZP341

Development stage: Discontinued
Lead developer: Jazz Pharmaceuticals
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

JZP341 is an investigational drug developed by Jazz Pharmaceuticals for the treatment of advanced or metastatic solid tumors. It has been described as a long-acting asparaginase bio-better, engineered to have improved pharmacokinetic properties such as increased serum half-life through the addition of a disordered proline-alanine-serine (PAS) tail[7]. In clinical trials, it has also been characterized as a DNA synthesis reducer with a novel mechanism of action[9]. The drug is administered intravenously and is being evaluated in adult patients who have not responded to standard treatments for their solid tumors[4][9].

Other names: long-acting recombinant Erwinia asparaginase JZP341long-acting Erwinia asparaginase

Targets

ASNase (L-asparaginase)

Beyond the preview

Go deeper on JZP341.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JZP341.

Explore the full profile